Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept.
about
Secondary treatment of acute graft-versus-host disease: a critical reviewReplacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease.Current and future approaches for control of graft-versus-host disease.Etanercept for steroid-refractory acute graft versus host disease following allogeneic hematopoietic stem cell transplantation.Tumor necrosis factor polymorphism affects transplantation outcome in patients with myelodysplastic syndrome but not in those with chronic myelogenous leukemia, independent of the presence of HLA-DR15.Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHD.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effectsTocilizumab for steroid refractory acute graft-versus-host diseaseAdvances in the understanding of acute graft-versus-host disease.Mucosal graft-vs-host disease.Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC).Advances in the treatment of acute graft-versus-host disease.Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins.The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation.Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation.Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: A multi-center prospective study.Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients.Extracorporeal photopheresis for the treatment of acute and chronic graft-versus-host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone MarrLow-dose MTX for the treatment of acute and chronic graft-versus-host disease in children.Etanercept for steroid-refractory acute graft-versus-host disease: A single center experience.Daclizumab for children with corticosteroid refractory graft-versus-host disease.Combination antithymocyte globulin and soluble TNFα inhibitor (etanercept) +/− mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease
P2860
Q26823275-8D60E86C-0B50-4E92-8C5E-ADF6865501B7Q33256286-2746D39F-46C5-41D3-9962-A44818F3FE17Q33642625-ADC7CABD-E932-4B1B-902D-DF6F0E3C00AFQ34184622-9F204D33-DD44-4EE1-8734-9B78A1B71E94Q34288677-96C79722-8146-404B-8071-C26D45F35C4BQ34441886-AC5C3E4B-2283-4024-ACF1-D81900EEB3B8Q35638252-8BF1BA18-44BE-42FF-ABC8-A66DE56F2FD7Q36113205-66A3FF00-8F58-4814-8DBC-D808ED767BAEQ36171750-231BF0E0-F688-472E-A197-4D7C15EFC7CAQ36380188-7A53DB53-9B93-44A5-B230-8DB6D1D1C34BQ36422339-131E7928-352E-4329-8E08-02912A53298CQ36759581-0A0EDCA9-DE42-40B4-87CB-8EADD16A835DQ36974835-A39231C0-7BD0-478F-85B4-ADFB273B4ACDQ37127527-0CC7D963-F311-4AA0-B737-F0C1457CDC03Q37191057-259965F1-C377-49CA-9A4B-7D266788387DQ37810286-19550CF8-E8D6-4102-A662-112BCEB4DE35Q37851519-6002CDD5-C117-489A-AD80-5F7F4056C7ECQ38066586-CCBF966E-69B4-4154-B94A-AA103090B6D9Q38839140-448D1284-0B39-4341-82B2-9EFF6C40DA24Q44397466-F8401555-2B51-4A1C-8020-9D200ABAEA08Q46584471-0D000034-0385-45DB-BB1E-80EAF234B72EQ46890990-BADBEF6A-B5F8-4E2E-9A52-6B6B300AF452Q47137561-8532CA32-FCAC-4C9C-BCA9-47F0E635BE79Q53652051-6E18DA5E-78EA-4D2C-92E8-0880E78BD795Q57252632-FDDF6CA3-46B5-450E-BAA2-9BF2EA45B6B4
P2860
Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Treatment of steroid-resistant ...... ith daclizumab and etanercept.
@ast
Treatment of steroid-resistant ...... ith daclizumab and etanercept.
@en
type
label
Treatment of steroid-resistant ...... ith daclizumab and etanercept.
@ast
Treatment of steroid-resistant ...... ith daclizumab and etanercept.
@en
prefLabel
Treatment of steroid-resistant ...... ith daclizumab and etanercept.
@ast
Treatment of steroid-resistant ...... ith daclizumab and etanercept.
@en
P2093
P2860
P356
P1476
Treatment of steroid-resistant ...... ith daclizumab and etanercept.
@en
P2093
Brenmoehl J
Hofmeister N
Junghanss C
Leithaeuser M
Roessler V
P2860
P2888
P304
P356
10.1038/SJ.BMT.1704929
P407
P577
2005-05-01T00:00:00Z
P5875
P6179
1045806031